Home

Our business strategy has been developed in direct response to unmet customer needs and emerging market trends for the delivery of injectable drugs and vaccines.


We recognize that injectable molecules are becoming more complex, therapeutic markets more competitive and regulatory agencies more focused on the overall quality and efficacy of the drug-device combination product. Most of all, we understand that patients, payors and prescribers are becoming more selective in their use of the safest, simplest and most convenient products available.


The traditional approach to develop ‘me-too’ commodity products under a ‘one-size fits all’ model is rapidly becoming obsolete as these, and other, market forces converge together. That is why we have created a new paradigm for injectable drug delivery that is customer-centric, patient-centric and outcomes focused.


At its core, our business strategy is very simple yet game-changing.  We out-innovate and out-perform the competition, developing game-changing products that can be leveraged by pharmaceutical companies to differentiate their injectable therapies so they can drive market share and maximize revenues.


Here are a few reasons why Unilife’s unique combination of innovative products, deep industry expertise, advanced operational capabilities and a dynamic business structure makes us a compelling choice to serve as your long-term partner for injectable drug delivery:


Range: To serve all injectable drug delivery needs for our pharmaceutical customers, we have established the most extensive product portfolio in our industry including prefilled syringes, dual-chamber syringes, auto-injectors, wearable injectors, intraocular delivery systems and novel devices;


Flexibility: We take a platform approach to product design whereby all base technologies are fully established and each product can be rapidly customized to address specific customer, drug or patient requirements;


IP Protection: To provide unrestricted freedom to operate for our customers and protection at the same time, we aggressively defend our large and rapidly growing portfolio of novel intellectual property in the U.S. and abroad;


Performance: To support customers throughout the clinical development and lifecycle management of their injectable therapies, we have a dynamic business structure operating with speed, agility and reliability;


Expertise: To respond quickly to customer requests and deliver high-quality products in accelerated timelines, each business unit is organized with all necessary cross-functional resources, deep industry knowledge and strong technical capabilities;


Efficiency: For compatibility with established pharmaceutical industrialization processes and equipment, we design every product for integration into standard filling and packaging processes and utilize well understood materials in the primary drug container; and


Quality: To exceed industry standards and the stringent program requirements of every customer, we operate within modern FDA-registered U.S. production facilities with all activities driven by a certified quality management system that is regularly audited by notified bodies, consultants and pharmaceutical companies.

Unilife is uniquely positioned to design, develop, manufacture and supply innovative, differentiated devices that can enable and enhance the delivery and commercial success of your injectable biologics, drugs and vaccines. We look forward to working with you.


Alan Shortall
CEO
Unilife

Email Us Follow Us Desktop Site